Latest Conference Articles

Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.

New findings show that the socioeconomic status of children with AML plays a significant and alarming roll in the rate of their overall survival after diagnosis.

Baseline laboratory values for AML clinical trials are setting unnecessary restrictions for kidney function that excludes African American patients with AML when this comorbidity does not impact overall survival.

Some patients with non-Hodgkin lymphoma may soon have a treatment option that could offer complete remission, according to new data presented at the American Society of Hematology 2019 Annual Meeting.

A dual-targeted chimeric antigen receptor-T cell therapy showed a more than 90% overall response rate in patients with relapsed or refractory disease.

JNJ-4528 showed deep responses and proved to be safe in patients with multiple myeloma, according to CARTITUDE-1 study findings.

Dr. Camillo Porta discussed what is new in kidney cancer beyond the first line of treatment at A Vision of Hope: A Kidney Cancer Educational Symposium.

Those with non-clear cell kidney cancer have much to look forward to as oncologists’ understanding of the disease is evolving.

Pre- and post-surgical treatment could benefit patients with kidney cancer who are at high risk for disease recurrence.

Nutrition plays a key role in kidney cancer; however, the need to address it is still unmet.

One expert explained what patients should know about their kidney cancer diagnosis at A Vision of Hope: A Kidney Cancer Educational Symposium.

“Survivors living with recurrent breast cancer have unique needs and programs that address these needs can enhance patient satisfaction,” the study authors wrote.

Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.

First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.

One in two patients with metastatic melanoma is alive five years following treatment with Opdivo plus Yervoy, according to long-term follow-up of the phase 3 CheckMate 067 trial.

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

First-line treatment with Opdivo plus low-dose Yervoy improved survival among patients with advanced NSCLC compared to chemotherapy, according to results from the CheckMate-227 trial.

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.

The executive director of the Cancer Policy Institute at the Cancer Support Community offers some candid advice for individuals who may be facing a new cancer diagnosis.

The merging of MyLifeLine.org with Cancer Support Community facilitates more comprehensive social and emotional support for patients and caregivers affected by cancer.

Treatment with fedratinib may lead to clinically meaningful responses among patients with myelofibrosis who were previously treated with Jakafi, according to an updated analysis of the phase 2 JAKARTA2 study.

Given with each dose of chemotherapy, trilaciclib temporarily puts bone marrow to sleep, helping to prevent fevers, infections and hospital stays in patients with small cell lung cancer.

Patients with breast cancer can still enroll in a clinical trial that is seeking to find the cause behind cardiac toxicity related to anthracycline-based treatment.

Researchers examined what goes into treatment decision-making for patients with multiple myeloma.

With new ways to treat chemotherapy-induced side effects, it seems that chemotherapy, combined with checkpoint inhibitors, is here to stay for the foreseeable future, according to one expert.

With a wealth of drugs available for the treatment of liver cancer, one expert explained how combination therapy may be where the future is headed.

One expert weighs the benefits and drawbacks of expanding clinical trials to be more inclusive and reflective of the general patient population with cancer.